Novartis AG

Swiss Stock Exchange:NOVN.SW

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

Location

Switzerland

Market Cap

USD 230.44 B

Share Price

USD 116.67

Avg Daily Volume

4,098,771

Change (1 day)

0.62%

Change (1 year)

11.05%

Change (YTD)

18.95%

Novartis AG EBIT for the year ending December 31, 2024: USD 14.65 B

Novartis AG EBIT is USD 14.65 B for the year ending December 31, 2024, a 46.78% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Novartis AG EBIT for the year ending December 31, 2023 was USD 9.98 B, a 25.08% change year over year.
Novartis AG EBIT for the year ending December 31, 2022 was USD 7.98 B, a -68.49% change year over year.
Novartis AG EBIT for the year ending December 31, 2021 was USD 25.32 B, a 135.57% change year over year.
Novartis AG EBIT for the year ending December 31, 2020 was USD 10.75 B, a 9.78% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Swiss Stock Exchange: NOVN.SW

Novartis AG

CEO	Dr. Vasant Narasimhan M.D.
IPO Date	Aug. 3, 1995
Location	Switzerland
Headquarters	Lichtstrasse 35
Employees	75,883
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials

Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.